[297 Pages Report] The global CIS insulin market is expected to reach US$ 465 Million by 2022. An increasing number of diabetic patients are estimated to further increase the demand for CIS insulin. During the forecast period ranging from 2022-2032, the market is projected to grow at a CAGR of 2.7%, totaling around US$ 600 Million by the end of 2032. As of 2021, the market was valued at US$ 455 Million, which experienced a Y-o-Y growth rate of 2.2% in 2022.
| Report Attribute | Key Statistics |
|---|---|
| Expected Base Year Value (2021) | US$ 455 Million |
| Anticipated Current Value (2022) | US$ 465 Million |
| Projected Forecast Value (2032) | US$ 600 Million |
| Global Growth Rate (2022-2032) | 2.7% CAGR |
Insulin is considered to be the main anabolic hormone of the body produced by beta cells in the pancreas. It regulates metabolism by promoting the absorption of glucose from the blood into the liver, fat, and skeletal muscle cells. Insufficient production of insulin leads to the accumulation of sugar in blood cells which causes diabetes.
The most common is type 2 diabetes, usually in adults, which occurs when the body becomes resistant to insulin or doesn't make enough insulin. In the past three decades, the prevalence of type 2 diabetes has risen dramatically in countries of all income levels. Type 1 diabetes, once known as juvenile diabetes or insulin-dependent diabetes, is a chronic condition in which the pancreas produces little or no insulin by itself.
Regionally, North America, spearheaded by the U.S. dominates the global CIS insulin market, during the forecast period. The market is likely to garner US$ 33 Million while exhibiting a CAGR of 3.4% from 2022 to 2032. Growth in the North American CIS Insulin market is driven by the increasing prevalence rate of diabetes and metabolic diseases, and the strong presence of leading CIS Insulin market players in the region.
On the other hand, Europe remains the world’s second-largest market for CIS insulin after North America. FMI’s latest CIS insulin market projections further reveal that countries like Germany, France, and the UK will emerge as the most lucrative markets for CIS insulin across Europe during the forecast period.
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
Increased spending on healthcare and advancements in healthcare infrastructure will continue to hold a positive influence on CIS insulin market growth
As per Future Market Insights, the global demand for the CIS Insulin market is anticipated to grow at a CAGR of 2.7% during the forecast period between 2022 and 2032, in comparison to a 2.2% CAGR registered from 2015 to 2021.
Growth in the CIS insulin market is driven by it the increasing prevalence of diabetes patients and changing lifestyles and eating habits resulting in health disorders such as obesity and other metabolic diseases, surging investments in R&D, innovations in insulin products, and a rise in CIS insulin applications for type I and type II diabetes.
Similarly, increasing government initiatives and investments to provide for high-quality diagnosis, particularly across developed nations like the United States, United Kingdom, and China will expand the CIS insulin market size during the forthcoming years.
According to the World Health Organization, about 422 million people worldwide have diabetes, the majority living in low-and middle-income countries, and 1.5 million deaths are directly attributed to diabetes each year. Both the number of cases and the prevalence of diabetes have been steadily increasing over the past few decades.
Despite optimistic growth projection, the global CIS insulin market is facing various obstacles that are restraining its growth to some extent. Some of these factors include the adverse effect of insulin therapy like hypoglycemia and pain at the site of injection may impact the use among some individuals.
Also, other disadvantages such as weight gain, electrolyte imbalance, and, in rare cases, peripheral hyperinsulinemia, decreased compliance, and high nocturnal glucose levels also lower the growth of the CIS insulin market. Increasing incidence of insulin resistance, particularly among obese individuals may restrain the growth of the market.
Principal Consultant
“Initiatives to curb diabetes to drive the CIS Insulin Market in the U.S”
Over the years, CIS insulin sales have risen at a substantial pace across US and the trend is likely to continue even during the forecast period, owing to the rapid surge in the number of diabetic people, due to the rising healthcare spending, favorable government initiatives, and presence of large number of CIS Insulin market players in the region.
North America is anticipated to lead the global CIS insulin market during the forecast period, with the U.S expected to lead across the region. As per Future Market Insights, the market in the U.S is likely to garner US$ 257 Million while exhibiting a CAGR of 4.6% from 2022 to 2032.
North America is expected to hold a large share in the global CIS insulin market due to the presence of leading technological advancements in the healthcare sector and increasing expenditure on healthcare by governments. Similarly, with an increase in the number of hospitals and healthcare facilities with the advancements in technology, many new products are being introduced in the global CIS insulin market will boost sales to new heights.
For instance, Novo Nordisk launched its smart insulin pen which comes with inbuilt Bluetooth. The smart pen can record the dose of insulin and maintain timely logs. The best part about this pen is that it does not pain that much when compared to normal insulin pens.
“Rapid technological advances in healthcare to boost the growth of the CIS insulin market in Europe”
As per FMI, the CIS insulin market in Europe is poised to exhibit strong growth on the back of surging technologically advanced research & treatment platforms for the diagnosis of chronic diseases, expanding healthcare infrastructure, and advancement in IT healthcare organizations. Also, increasing awareness and greater spending on healthcare treatments and procedures. With such as acceleration in the healthcare industry, manufacturers of CIS insulin are focusing on leading economies to strengthen their market footprint globally.
The rapid technological development and extensive government initiatives for the production and the regulation of price increases will boost the growth of the CIS insulin market across Europe during the forthcoming period. Amongst all countries, the U.K is slated to emerge as the most lucrative in Europe, expected to flourish at a 3.4% CAGR until 2032, reaching US$ 33 Million.
“Rapid Acting CIS Insulin to experience Maximum Uptake”
Based on product type, rapid-acting CIS insulin is likely to account for maximum growth, growing at a 2.2% CAGR. As rapid-acting insulins work very quickly to minimize the rise in blood sugar after eating and their effect lasts for a couple of hours. This type of insulin is often used with longer-acting insulin for maintaining blood glucose for a longer period.
Rapid-acting insulin replaces the insulin that is normally produced by the body and by helping sugar move from the blood into other body tissues where it is used for energy inhibiting the liver from producing more sugar is another factor that makes them a preferred choice among physicians as well as patients. This will boost the demand for the segment in the forecasting period.
“Treatment for Type I and other Diabetes to Contribute a Significant Portion to Market Growth”
Based on application, FMI’s latest report on the CIS insulin market forecast Type I and Other Diabetes segment to grow at a CAGR of 2.1% during the assessment period. The increasing diagnosis rate of type I and other diabetes boost the growth of the segment.
According to the International Diabetic Federation around 10% of all people with diabetes have type 1 diabetes. All people with type 1 diabetes need to take insulin to control their blood glucose levels. Increasing the production of insulin in developed countries and various new products will boost the growth of the segment.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Some of the leading cis insulin include Novo Nordisk, Sanofi, Eli Lilly, Bristol-Myers Squibb and Novartis among others. These key CIS Insulin providers are adopting various strategies such as new product launches and approvals, partnerships, collaborations, acquisitions, mergers, etc. to increase their sales and gain a competitive edge in the global CIS Insulin market.
| Report Attribute | Details |
|---|---|
| Growth Rate | 2.7% CAGR from 2022 to 2032 |
| Market Value for 2022 | US$ 465 Million |
| Market Value for 2032 | US$ 600 Million |
| Base Year for Estimation | 2021 |
| Historical Data | 2015-2021 |
| Forecast Period | 2022-2032 |
| Quantitative Units | US$ Million for Value |
| Report Coverage | Revenue Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends, and Pricing Analysis |
| Segments Covered |
|
| Regions Covered |
|
| Key Countries Profiled |
|
| Key Companies Profiled |
|
| Report Customization & Pricing | Available upon Request |
The global CIS insulin market is likely to reach US$ 465 Million in 2022
As per FMI, the CIS insulin industry is expected to grow at a CAGR of 2.7% throughout the forecast period (2022-2032).
The global sales of CIS insulin systems are anticipated to total a valuation of US$ 600 Million by 2032.
Some of the leading CIS insulin manufacturers include Novo Nordisk, Sanofi, Eli Lilly, Bristol-Myers Squibb, and Novartis
U.S will continue to remain the most lucrative market for CIS insulin accounting for the market value of US$ 257Million 2032
Increasing technological advancement in the healthcare sector and an increase in the incidence of diabetes patients are some of the major factors shaping the growth of the CIS insulin market.
1. Executive Summary 1.1. Global Market Outlook 1.2. Summary of Statistics 1.3. Key Market Characteristics & Attributes 1.4. Analysis and Recommendations 2. Market Overview 2.1. Market Coverage / Taxonomy 2.2. Market Definition / Scope / Limitations 3. Market Risks and Trends Assessment 3.1. Risk Assessment 3.1.1. COVID-19 Crisis and Impact on Market 3.1.2. COVID-19 Impact Benchmark with Previous Crisis 3.1.3. Impact on Market Value (US$ Mn) 3.1.4. Assessment by Key Countries 3.1.5. Assessment by Key Market Segments 3.1.6. Action Points and Recommendation for Suppliers 3.2. Key Trends Impacting the Market 3.3. Formulation and Product Development Trends 4. Market Background 4.1. Market, by Key Countries 4.2. Market Opportunity Assessment (US$ Mn) 4.2.1. Total Available Market 4.2.2. Serviceable Addressable Market 4.2.3. Serviceable Obtainable Market 4.3. Market Scenario Forecast 4.3.1. Demand in optimistic Scenario 4.3.2. Demand in Likely Scenario 4.3.3. Demand in Conservative Scenario 4.4. Investment Feasibility Analysis 4.4.1. Investment in Established Markets 4.4.1.1. In Short Term 4.4.1.2. In Long Term 4.4.2. Investment in Emerging Markets 4.4.2.1. In Short Term 4.4.2.2. In Long Term 4.5. Forecast Factors - Relevance & Impact 4.5.1. Top Companies Historical Growth 4.5.2. Growth in Automation, By Country 4.5.3. Market Adoption Rate, By Country 4.6. Market Dynamics 4.6.1. Market Driving Factors and Impact Assessment 4.6.2. Prominent Market Challenges and Impact Assessment 4.6.3. Market Opportunities 4.6.4. Prominent Trends in the Global Market & Their Impact Assessment 5. Key Success Factors 5.1. Manufacturers’ Focus on Low Penetration High Growth Markets 5.2. Banking on with Segments High Incremental Opportunity 5.3. Peer Benchmarking 6. Global Market Demand Analysis 2015-2021 and Forecast, 2022-2032 6.1. Historical Market Analysis, 2015-2021 6.2. Current and Future Market Projections, 2022-2032 6.3. Y-o-Y Growth Trend Analysis 7. Global Market Value Analysis 2015-2021 and Forecast, 2022-2032 7.1. Historical Market Value (US$ Mn) Analysis, 2015-2021 7.2. Current and Future Market Value (US$ Mn) Projections, 2022-2032 7.2.1. Y-o-Y Growth Trend Analysis 7.2.2. Absolute $ Opportunity Analysis 8. Global Market Analysis 2015-2021 and Forecast 2022-2032, By Product Type 8.1. Introduction / Key Findings 8.2. Historical Market Size (US$ Mn) Analysis By Product Type, 2015-2021 8.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Product Type, 2022-2032 8.3.1. Rapid acting 8.3.2. Long acting 8.3.3. Premixed 8.3.4. Premixed analog 8.3.5. Short acting 8.3.6. Intermediate acting 8.4. Market Attractiveness Analysis By Product Type 9. Global Market Analysis 2015-2021 and Forecast 2022-2032, By Application 9.1. Introduction / Key Findings 9.2. Historical Market Size (US$ Mn) Analysis By Application, 2015-2021 9.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Application, 2022-2032 9.3.1. Type I and Other Diabetes 9.3.2. Type II Diabetes 9.4. Market Attractiveness Analysis By Application 10. Global Market Analysis 2015-2021 and Forecast 2022-2032, By Source 10.1. Introduction / Key Findings 10.2. Historical Market Size (US$ Mn) Analysis By Source, 2015-2021 10.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Source, 2022-2032 10.3.1. Human Recombinant Insulin 10.3.2. Analogs 10.4. Market Attractiveness Analysis By Source 11. Global Market Analysis 2015-2021 and Forecast 2022-2032, By Region 11.1. Introduction 11.2. Historical Market Size (US$ Mn) Analysis By Region, 2015-2021 11.3. Current Market Size (US$ Mn) & Analysis and Forecast By Region, 2022-2032 11.3.1. North America 11.3.2. Latin America 11.3.3. Europe 11.3.4. Asia Pacific 11.3.5. Middle East and Africa (MEA) 11.4. Market Attractiveness Analysis By Region 12. North America Market Analysis 2015-2021 and Forecast 2022-2032 12.1. Introduction 12.2. Pricing Analysis 12.3. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2015-2021 12.4. Market Size (US$ Mn) & Forecast By Market Taxonomy, 2022-2032 12.4.1. By Country 12.4.1.1. U.S. 12.4.1.2. Canada 12.4.1.3. Rest of North America 12.4.2. By Product Type 12.4.3. By Source 12.4.4. By Application 12.5. Market Attractiveness Analysis 12.5.1. By Country 12.5.2. By Product Type 12.5.3. By Source 12.5.4. By Application 13. Latin America Market Analysis 2015-2021 and Forecast 2022-2032 13.1. Introduction 13.2. Pricing Analysis 13.3. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2015-2021 13.4. Market Size (US$ Mn) & Forecast By Market Taxonomy, 2022-2032 13.4.1. By Country 13.4.1.1. Brazil 13.4.1.2. Mexico 13.4.1.3. Rest of Latin America 13.4.2. By Product Type 13.4.3. By Source 13.4.4. By Application 13.5. Market Attractiveness Analysis 13.5.1. By Country 13.5.2. By Product Type 13.5.3. By Source 13.5.4. By Application 14. Europe Market Analysis 2015-2021 and Forecast 2022-2032 14.1. Introduction 14.2. Pricing Analysis 14.3. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2015-2021 14.4. Market Size (US$ Mn) & Forecast By Market Taxonomy, 2022-2032 14.4.1. By Country 14.4.1.1. Germany 14.4.1.2. France 14.4.1.3. U.K. 14.4.1.4. Italy 14.4.1.5. Benelux 14.4.1.6. Nordic Countries 14.4.1.7. Rest of Europe 14.4.2. By Product Type 14.4.3. By Source 14.4.4. By Application 14.5. Market Attractiveness Analysis 14.5.1. By Country 14.5.2. By Product Type 14.5.3. By Source 14.5.4. By Application 15. Asia Pacific Market Analysis 2015-2021 and Forecast 2022-2032 15.1. Introduction 15.2. Pricing Analysis 15.3. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2015-2021 15.4. Market Size (US$ Mn) & Forecast By Market Taxonomy, 2022-2032 15.4.1. By Country 15.4.1.1. China 15.4.1.2. Japan 15.4.1.3. South Korea 15.4.1.4. Rest of Asia Pacific 15.4.2. By Product Type 15.4.3. By Source 15.4.4. By Application 15.5. Market Attractiveness Analysis 15.5.1. By Country 15.5.2. By Product Type 15.5.3. By Source 15.5.4. By Application 16. Middle East and Africa Market Analysis 2015-2021 and Forecast 2022-2032 16.1. Introduction 16.2. Pricing Analysis 16.3. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2015-2021 16.4. Market Size (US$ Mn) & Forecast By Market Taxonomy, 2022-2032 16.4.1. By Country 16.4.1.1. GCC Countries 16.4.1.2. South Africa 16.4.1.3. Turkey 16.4.1.4. Rest of Middle East and Africa 16.4.2. By Product Type 16.4.3. By Source 16.4.4. By Application 16.5. Market Attractiveness Analysis 16.5.1. By Country 16.5.2. By Product Type 16.5.3. By Source 16.5.4. By Application 17. Key Countries Market Analysis 2015-2021 and Forecast 2022-2032 17.1. Introduction 17.1.1. Market Value Proportion Analysis, By Key Countries 17.1.2. Global Vs. Country Growth Comparison 17.2. US Market Analysis 17.2.1. Value Proportion Analysis by Market Taxonomy 17.2.2. Value & Analysis and Forecast by Market Taxonomy, 2015-2032 17.2.2.1. By Product Type 17.2.2.2. By Source 17.2.2.3. By Application 17.3. Canada Market Analysis 17.3.1. Value Proportion Analysis by Market Taxonomy 17.3.2. Value & Analysis and Forecast by Market Taxonomy, 2015-2032 17.3.2.1. By Product Type 17.3.2.2. By Source 17.3.2.3. By Application 17.4. Mexico Market Analysis 17.4.1. Value Proportion Analysis by Market Taxonomy 17.4.2. Value & Analysis and Forecast by Market Taxonomy, 2015-2032 17.4.2.1. By Product Type 17.4.2.2. By Source 17.4.2.3. By Application 17.5. Brazil Market Analysis 17.5.1. Value Proportion Analysis by Market Taxonomy 17.5.2. Value & Analysis and Forecast by Market Taxonomy, 2015-2032 17.5.2.1. By Product Type 17.5.2.2. By Source 17.5.2.3. By Application 17.6. Germany Market Analysis 17.6.1. Value Proportion Analysis by Market Taxonomy 17.6.2. Value & Analysis and Forecast by Market Taxonomy, 2015-2032 17.6.2.1. By Product Type 17.6.2.2. By Source 17.6.2.3. By Application 17.7. France Market Analysis 17.7.1. Value Proportion Analysis by Market Taxonomy 17.7.2. Value & Analysis and Forecast by Market Taxonomy, 2015-2032 17.7.2.1. By Product Type 17.7.2.2. By Source 17.7.2.3. By Application 17.8. Italy Market Analysis 17.8.1. Value Proportion Analysis by Market Taxonomy 17.8.2. Value & Analysis and Forecast by Market Taxonomy, 2015-2032 17.8.2.1. By Product Type 17.8.2.2. By Source 17.8.2.3. By Application 17.9. BENELUX Market Analysis 17.9.1. Value Proportion Analysis by Market Taxonomy 17.9.2. Value & Analysis and Forecast by Market Taxonomy, 2015-2032 17.9.2.1. By Product Type 17.9.2.2. By Source 17.9.2.3. By Application 17.10. UK Market Analysis 17.10.1. Value Proportion Analysis by Market Taxonomy 17.10.2. Value & Analysis and Forecast by Market Taxonomy, 2015-2032 17.10.2.1. By Product Type 17.10.2.2. By Source 17.10.2.3. By Application 17.11. Nordic Countries Market Analysis 17.11.1. Value Proportion Analysis by Market Taxonomy 17.11.2. Value & Analysis and Forecast by Market Taxonomy, 2015-2032 17.11.2.1. By Product Type 17.11.2.2. By Source 17.11.2.3. By Application 17.12. China Market Analysis 17.12.1. Value Proportion Analysis by Market Taxonomy 17.12.2. Value & Analysis and Forecast by Market Taxonomy, 2015-2032 17.12.2.1. By Product Type 17.12.2.2. By Source 17.12.2.3. By Application 17.13. Japan Market Analysis 17.13.1. Value Proportion Analysis by Market Taxonomy 17.13.2. Value & Analysis and Forecast by Market Taxonomy, 2015-2032 17.13.2.1. By Product Type 17.13.2.2. By Source 17.13.2.3. By Application 17.14. South Korea Market Analysis 17.14.1. Value Proportion Analysis by Market Taxonomy 17.14.2. Value & Analysis and Forecast by Market Taxonomy, 2015-2032 17.14.2.1. By Product Type 17.14.2.2. By Source 17.14.2.3. By Application 17.15. GCC Countries Market Analysis 17.15.1. Value Proportion Analysis by Market Taxonomy 17.15.2. Value & Analysis and Forecast by Market Taxonomy, 2015-2032 17.15.2.1. By Product Type 17.15.2.2. By Source 17.15.2.3. By Application 17.16. South Africa Market Analysis 17.16.1. Value Proportion Analysis by Market Taxonomy 17.16.2. Value & Analysis and Forecast by Market Taxonomy, 2015-2032 17.16.2.1. By Product Type 17.16.2.2. By Source 17.16.2.3. By Application 17.17. Turkey Market Analysis 17.17.1. Value Proportion Analysis by Market Taxonomy 17.17.2. Value & Analysis and Forecast by Market Taxonomy, 2015-2032 17.17.2.1. By Product Type 17.17.2.2. By Source 17.17.2.3. By Application 17.17.3. Competition Landscape and Player Concentration in the Country 18. Market Structure Analysis 18.1. Market Analysis by Tier of Companies 18.2. Market Concentration 18.3. Market Share Analysis of Top Players 18.4. Market Presence Analysis 18.4.1. By Regional footprint of Players 18.4.2. Product footprint by Players 19. Competition Analysis 19.1. Competition Dashboard 19.2. Competition Benchmarking 19.3. Competition Deep Dive 19.3.1. Novo Nordisk 19.3.1.1. Overview 19.3.1.2. Product Portfolio 19.3.1.3. Sales Footprint 19.3.1.4. Strategy Overview 19.3.2. Sanofi 19.3.2.1. Overview 19.3.2.2. Product Portfolio 19.3.2.3. Sales Footprint 19.3.2.4. Strategy Overview 19.3.3. Eli Lilly 19.3.3.1. Overview 19.3.3.2. Product Portfolio 19.3.3.3. Sales Footprint 19.3.3.4. Strategy Overview 19.3.4. Bristol-Myers Squibb 19.3.4.1. Overview 19.3.4.2. Product Portfolio 19.3.4.3. Sales Footprint 19.3.4.4. Strategy Overview 19.3.5. Novartis 19.3.5.1. Overview 19.3.5.2. Product Portfolio 19.3.5.3. Sales Footprint 19.3.5.4. Strategy Overview 19.3.6. Takeda Pharmaceuticals 19.3.6.1. Overview 19.3.6.2. Product Portfolio 19.3.6.3. Sales Footprint 19.3.6.4. Strategy Overview 19.3.7. Boehringer Ingelheim 19.3.7.1. Overview 19.3.7.2. Product Portfolio 19.3.7.3. Sales Footprint 19.3.7.4. Strategy Overview 19.3.8. Biocon 19.3.8.1. Overview 19.3.8.2. Product Portfolio 19.3.8.3. Sales Footprint 19.3.8.4. Strategy Overview 19.3.9. Dongbao Enterprise Group Co., Ltd. 19.3.9.1. Overview 19.3.9.2. Product Portfolio 19.3.9.3. Sales Footprint 19.3.9.4. Strategy Overvie 19.3.10. Merck KGaA 19.3.10.1. Overview 19.3.10.2. Product Portfolio 19.3.10.3. Sales Footprint 19.3.10.4. Strategy Overview 19.3.11. Oramed Pharmaceuticals Inc. 19.3.11.1. Overview 19.3.11.2. Product Portfolio 19.3.11.3. Sales Footprint 19.3.11.4. Strategy Overview 19.3.12. Halozyme Therapeutics 19.3.12.1. Overview 19.3.12.2. Product Portfolio 19.3.12.3. Sales Footprint 19.3.12.4. Strategy Overview 19.3.13. Wanbang Biopharma 19.3.13.1. Overview 19.3.13.2. Product Portfolio 19.3.13.3. Sales Footprint 19.3.13.4. Strategy Overview 19.3.14. Xinbai Pharmaceutical 19.3.14.1. Overview 19.3.14.2. Product Portfolio 19.3.14.3. Sales Footprint 19.3.14.4. Strategy Overview 19.3.15. Gan & Lee Pharmaceutical 19.3.15.1. Overview 19.3.15.2. Product Portfolio 19.3.15.3. Sales Footprint 19.3.15.4. Strategy Overview 19.3.16. Indrar 19.3.16.1. Overview 19.3.16.2. Product Portfolio 19.3.16.3. Sales Footprint 19.3.16.4. Strategy Overview 19.3.17. Farmak 19.3.17.1. Overview 19.3.17.2. Product Portfolio 19.3.17.3. Sales Footprint 19.3.17.4. Strategy Overview 20. Assumptions and Acronyms Used 21. Research Methodology
Explore Healthcare Insights
View Reports
CIS Insulin Market
